Promising new treatment for life threatening acute respiratory distress syndrome (ARDS)

Turku – Finland, January 2, 2013. Together with its network of scientists and clinicians Faron Pharmaceuticals Ltd. has developed a promising new treatment for life threatening acute respiratory distress syndrome (ARDS). The FPCLI001 study, which reduced the odds of all cause mortality by more than 80 percent among the ARDS patients, has been published online in the distinguished medical journal: The Lancet Respiratory Medicine. Acute respiratory distress syndrome (ARDS) is the major cause of death in intensive care units. It is estimated that approximately 300 – 400 thousand people